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Abstract   
 
Background:  Chronic kidney disease (CKD) is common, important and associated 
with increased healthcare needs due to CKD progression. Definitions of renal disease 
progression are multiple, and not always comparable. A measure of ‘progression’ 
directly comparable to RRT initiation would identify ‘progressors’ in research and for 
healthcare planning.  
Methods: GLOMMS-I is a community cohort with CKD from 2003, followed up to 
June 2009 for (i) RRT initiation and (ii) ‘progression’: sustained reduction in eGFR by 
15ml/min/1.73m2 (equivalent to CKD stage change), or to less than 10ml/min/1.73m2, 
whichever occurs first.  Predictors were baseline demographics and comorbidity. The 
use of the KDIGO-2012 progression definition was also explored. 
Results:  2289 and 1044 had stage 3 and 4 CKD, 44% male. Overall, RRT initiation and 
progression rates were 0.97 and 3.50 per 100 patient-years. Females had significantly 
lower progression and RRT initiation rates. Progression rate was not dependent on CKD 
stage (incidence-rate-ratio (IRR) for stage 4 (versus stage 3) 0.9 (95% CI 0.8–1.2)), 
whereas RRT initiation rate was (IRR 5.6 (95% CI 3.8–8.2)). Increased proteinuria was 
associated with both greater RRT initiation and progression rates.  
Conclusion:  Progression and RRT initiation rate ratios allow comparison of predictors 
of these outcomes. Higher rates of both in males suggest that greater RRT initiation rate 
is biological rather than due to preferential treatment. Similar progression but very 
different RRT initiation rates in stage 3 and 4 CKD, suggest that CKD stage effect on 
RRT initiation is a function of endpoint proximity rather than faster renal function 
deterioration. 
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Chronic kidney disease (CKD) is common and important due to progression of renal 
disease, eventually to renal replacement therapy (RRT) initiation. Comparison of 
predictors of progression and RRT initiation suggest that the preferential initiation of 
RRT in males is the result of faster progression. The same for stage 3 and 4 CKD 
suggests that preferential RRT initiation in stage 4 versus 3 CKD is a result of proximity 
to the RRT initiation endpoint rather than faster progression. 
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Introduction 
 
Chronic kidney disease (CKD) is common, and an important health issue because of its 
association with increased risk for end-stage renal disease (ESRD), renal replacement 
therapy (RRT) and mortality1. In 2002, KDOQI1 defined five stages of CKD, 
subsequent divisions to stage 3 (3a and 3b) grouped renal function into 
15ml/min/1.73m2 glomerular filtration rate (GFR) bands. Historically it was believed 
that once CKD was established, there was progressive decline of GFR1,2 linearly over 
time2,3. This is now less clear, as a growing number of studies report that not all people 
with CKD initiate RRT or die during follow-up4-6. The health impacts of CKD are not 
restricted to ESRD.  Before reaching ESRD, there is an increase in the risk of clinically 
important complications, including anaemia7, acidosis8,9, bone disease7 and 
cardiovascular events, all having their own complications and costs10,11. It is therefore 
important to be able to define kidney function deterioration as a potential predictor for 
future outcomes such as initiation of RRT and poorer health outcomes requiring clinical 
intervention. 
 
KDOQI 2002 guidelines1 defined progression as “either (1) decline in the level of 
kidney function, … in a patient who has been followed longitudinally … , or (2) onset of 
kidney failure, defined by initiation of kidney replacement therapy, either for symptoms 
or complications of decreased kidney function”. Whilst this clinical concept of 
progression is clear, operationalisation of the definition for research and clinical 
practice use is more complex, and reflected by the large number of published 
approaches.  Clinical trials have used doubling of creatinine12; 50% and 25% reductions 
in GFR13. Some report the mean annual change of eGFR over follow-up time, often 
using just the first and last eGFR measurement. The time spent moving from one stage 
to the next has been also been reported14.  The National Institute for Health and Clinical 
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Excellence15 suggested progression be identified by obtaining at least three GFRs over a 
period of not less than 90 days, and defined progression as a decline in eGFR of more 
than 5ml/min/1.73m2 within one year, or more than 10ml/min/1.73m2 within five years. 
In January 2013, KDIGO released new 2012 CKD guidelines16. One definition of 
progression outlined was “a certain drop in eGFR … a drop in GFR category 
accompanied by a 25% or greater drop in eGFR from baseline”.  
The relationship between these operational definitions of progression and the initiation 
of RRT is difficult to understand, both in terms of research endpoints and in translating 
evidence into clinical practice. They highlight the need for a definition of progression 
that is consistent in terms of the size of the function loss, is associated with an increased 
risk of developing RRT, specifies a chronic change in function and can be translated 
simply into clinical and epidemiological practice. 
  
In this paper, we propose a definition of increased risk to be the time to achieve a 
reduction in the eGFR equivalent of dropping a full CKD stage, 15ml/min/1.73m2, and 
that the deterioration is sustained.  We test the application of this novel definition of 
progression as a marker of significant renal function decline, comparing it to RRT 
initiation rate. We report the predictors of progression in a large, well characterised, 
population based cohort6. 
Subjects and Methods 
The first Grampian Laboratory Outcomes Morbidity and Mortality Study (GLOMMS-I) 
cohort has been described elsewhere6. Adults (aged over 15 years) resident in Grampian 
(a single health authority region with single biochemistry service, in the North East of 
Scotland, UK), with abnormal renal function tests (an “index” creatinine above 
150µmol/l for men and 130µmol/l for women measured from January to June 2003) 
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were identified (n=5538). Those on RRT at index were excluded. Results of those with 
AKI are reported elsewhere17. Individuals with CKD were identified and included in 
GLOMMS-I if they had at least three depressed eGFR values (median eGFR below 
60ml/min/1.73m2) documented over at least three months either before or after the 
index creatinine (3426 individuals). Casenote review provided baseline comorbidity. 
Regional health administration systems recorded all RRT provision, admissions, 
discharges, outpatient attendances and death registrations. Data linkage between these 
systems and the cohort took place to allow follow-up to the 30th June 2009.  
 
GLOMMS-I was approved by the University of Aberdeen Research Ethics Committee, 
the NHS Grampian Caldicott Guardian and discussed with the North of Scotland NHS 
Research Ethics Committee. 
 
Inclusions and exclusions 
Individuals with stage 3 or 4 CKD were included in this analysis (an eGFR 
<15ml/min/1.73m2 was considered too low to assess progression). Those who died on 
the index date were excluded.  
 
Definition of “progression” 
The sustained reduction in eGFR of 15ml/min/1.73m2 is the equivalent of a change in 
CKD stage. An eGFR of <10ml/min/1.73m2 equates to a need to initiate RRT for many, 
therefore a relevant end-point for those with more advanced CKD.  Progression was 
therefore defined as having achieved either a sustained reduction in eGFR by 
15ml/min/1.73m2 (Figure 1) or to less than 10ml/min/1.73m2, whichever occurred first.  
The reduction in eGFR was deemed sustained if the median eGFR afterwards (for all 
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eGFRs until RRT initiation, death, or end of follow-up) was also below this value. The 
KDIGO-2012 definition of progression (a 25% reduction in eGFR and change in CKD 
stage from baseline) was also applied, again this change needed to be sustained.  
 
 
Outcomes and follow-up 
Outcomes of interest were times to “progression” and initiation of RRT. All creatinine 
measurements in Grampian and thus eGFR values for an individual from index to end 
of follow-up were available. Follow-up was truncated at midnight 30th June 2009, six 
years from the end of the index period.  Vital status at this point was noted as was the 
last eGFR in those still alive not on RRT. Date of last use of NHS Grampian services 
was checked to ensure full follow-up. 
 
Covariates 
The potential predictors of interest were baseline age, sex, CKD stage, proteinuria 
status, comorbidities and smoking status. Age and sex were derived from the data at the 
index creatinine. Baseline CKD stage was assigned based on the index eGFR: stage 3 
(30-59 [3a (45-59), 3b (30-44)]ml/min/1.73m2); and stage 4 (15-29ml/min/1.73m2). 
Proteinuria status was categorised based on the last available albumin or protein 
creatinine ratio (ACR or PCR) up to and including the index creatinine date. 
Microalbuminuria was considered present if ACR was ≥2.5mg/mmol for men, 
≥3.5mg/mmol for women; macroalbuminuria if ACR ≥30mg/mmol or PCR 
≥50mg/mmol; and normoalbuminuria where either ACR or PCR were measured and the 
definitions of micro or macroalbuminuria not met. If there were no measurements of 
ACR or PCR prior to index, these variables were categorised as untested. Comorbidities 
(Table 1 and Table 2) were recorded as absent or present from casenote review. 
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Data linkage and assumptions 
Each individual had a basic record of demographics, and a Community Health Index 
(CHI) and hospital number. CHI is a unique identifier assigned to all residents of 
Scotland registered with a General Practitioner and used at almost every healthcare 
facility and interaction. Mortality data were obtained by deterministic linkage to health 
board data using CHI number. RRT data were obtained by linkage to the local renal 
management system. All biochemistry samples were linked on a minimum of three 
identifiers to known individuals.  Longitudinal records for each individual were created 
and CHI deterministic linkage used to link to the basic record for a given individual. 
The use of CHI for linkage minimises the risk of incorrectly linking two individuals 
who have the same gender, name and date of birth.  
 
Analysis 
For ease of understanding of overall outcome, the first outcome by the end of follow-up 
was checked, including death and RRT initiation. If these end points were not reached 
then the final eGFR measurement was used as a basic check to determine whether there 
had been a change in eGFR stage during follow-up.  To allow assessment of whether 
the new sustained progression definition might be a valid, early marker of renal function 
deterioration, (and thus the need for RRT initiation) with similar predictors, the times to 
both progression and RRT initiation were calculated for each individual who reached 
these outcomes. The follow-up, with censoring at either death, end of follow-up or the 
end-point of progression or RRT initiation was calculated separately for the two 
outcomes. The progression rate, per 100 patient-years (py) follow-up, was calculated 
from the numbers achieving progression (sustained eGFR drop) and the follow-up time 
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for this outcome. KDIGO-2012 defined progression rate was also calculated in this way. 
The rate of RRT initiation per 100py was calculated from the numbers initiating RRT 
and the follow-up time for this outcome. The characteristics of those who progressed 
and those who did not were compared with Chi squared and Mann-Whitney tests as 
appropriate. The association between having initiated RRT and having progressed by 
the end of follow-up was expressed with risk ratios (RR). Kaplan-Meier survival plots 
were created. Stratification (with Mantel-Haenszel summary rate ratios) and Poisson 
models were used to explore the effect of baseline characteristics on progression (both 
15ml/min/1.73m2 drop and KDIGO-2012 defined) and RRT initiation outcomes 
separately. The effects of comorbidities on these outcomes were expressed as rate 
ratios. 
 
 
Results 
 
Of 3426 in the cohort, 12 individuals who died on index date and 92 who had stage 5 
CKD were excluded. There were 3322 individuals (2289 stage 3 and 1044 stage 4) at 
baseline, 44% were male. Most (3102) individuals had a further eGFR after the index, 
the median number of further eGFR values prior to RRT initiation, death or end of 
follow-up was 18 (range zero to 525). The majority had died by the end of six years 
follow-up (Figure 2), 124 had initiated RRT. The final eGFR CKD stage was no worse 
for 30% of those with stage 3 at index, and 23% of those with stage 4 at index.  
 
Progression 
Overall, 1027 (31%) had a 15ml/min/1.73m2 and 1481 (45%) a 25% drop in eGFR and 
CKD stage change. However most changes were not sustained, only 13.1% met our new 
definition of progression (characteristics in Table 1), and 13.0% the KDIGO-2012 
 10 
 
definition. The majority of the cohort was female; however the majority of progressors 
were male. More progressors had macroalbuminuria at baseline.  
 
The rates of initiating RRT and progression are shown by baseline characteristics in 
Table 2.  The incidence rate ratios (IRRs) for progression by baseline characteristics are 
also shown in Table 2, as are IRRs for RRT, for comparison. The overall rates for 
initiating RRT and progressing (our definition) were 0.97 and 3.50 per 100py 
respectively. The higher rate of RRT initiation in males was supported by a higher rate 
of progression also, with a statistically significant low IRR for females versus males of 
0.61 (95% CI 0.50-0.74) reflecting a similar IRR for RRT initiation. Macroalbuminuria 
was associated with higher rates of RRT initiation and also higher rates of progression 
with an IRR of 3.20 (95% CI 2.25-4.55) even after adjustment for other factors. 
Smokers had a statistically significant increase in rates of progression compared to non-
smokers. Those with a haematological malignancy had a significantly higher rate of 
progression than those without; although there was no difference in RRT initiation rates. 
   
Outcome by progression status is shown in Table 3. Of those who progressed, 21.4% 
(13.1% and 44.7% of stage 3 and 4 respectively) initiated RRT, compared to 1.1% of 
those who had not progressed. Progressors had an unadjusted RR for RRT initiation of 
19.9 (95% CI 13.4-29.5) compared to non-progressors (RR using the KDIGO-2012 
definition was 9.6 (95% CI 6.8-13.5)).  1145 (34.4%) individuals were still alive at the 
end of follow-up and did not meet this definition of progression (similar to that 
identified by the last CKD stage).  
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For KDIGO-2012 defined progression, the baseline characteristics of the 432 who met 
the definition (not published here) were almost identical to those above except only 70 
(16.2%) of KDIGO progressors had CKD stage 4 disease at baseline compared to 114 
(26.2%) of progression defined by a 15ml/min/1.73m2 drop in eGFR. Also less 
individuals identified as progressors initiated RRT (73 vs 93). Rates of progression 
based on the KDIGO definition were similar to those identified by our definition (Table 
2), as were the IRRs for each exposure. Exceptions to this were that stage 4 CKD 
appeared to become protective from progression as defined by KDIGO, ex-smokers had 
more progression and low levels of urinary protein were not predictive of KDIGO 
defined progression. Kaplan-Meier progression survival plots (adjusted for age sex and 
proteinuria status) by CKD stage show little difference between CKD stages based on 
our definition, however for the KDIGO-based definition those with stage 3 CKD had a 
worse progression prognosis than those with stage 4 (Figure 3). 
 
 
Discussion 
In this article, we propose a definition of renal disease progression which, to our 
knowledge, has not been used before.  We have demonstrated that it can be used to 
describe individuals who have worsening renal function prior to the initiation of RRT, 
thus allowing assessment of the predictors of worsening renal function rather than the 
current reliance on initiation of RRT as a late outcome.   The definition is based on a 
sustained drop in eGFR of 15ml/min/1.73m2, equivalent of a stage change. The use of a 
lower threshold of 10ml/min/1.73m2 acknowledges that at lower levels of function the 
amount of further loss possible is less. The association between our novel definition and 
the risk of future RRT supports its value as a potential early predictor of those at risk of 
RRT. It may also mark a need for increased healthcare support. 
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The majority of individuals with stage 3 and 4 CKD died. A small minority went on to 
initiate RRT. Of the 36.6% with stage 3 and 4 disease that neither died nor started RRT, 
the majority did not progress during the six years of follow-up.   
 
Progression, defined by the sustained loss of eGFR of either 15ml/min/1.73m2 or to 
10ml/min/1.73m2 whichever occurs first, was associated with subsequent need to 
initiate RRT (20-fold increase in risk), compared to non-progression. We found that 
males had a higher rate of progression than females. There has long been a suggestion 
that males initiate RRT at a greater rate than females. If males progress at a faster rate, 
as evidenced here, then it would seem appropriate that they initiate RRT faster also. A 
different pathological process or risk profile may be involved. 
 
 The finding that macroalbuminuria is a predictor of faster progression as well as the 
initiation of RRT is reassuring, reflecting the findings of others18,19. It also supports the 
use of treatments aimed at reducing proteinuria to reduce the initiation of RRT and 
progression. 
 
Using our definition, the progression rates for CKD stage 3 and 4 are very similar 
despite very different RRT initiation rates. This suggests that the differential in RRT 
initiation rates for CKD stage reflects lead-time bias with more advanced CKD having 
less far to go before requiring RRT rather than inherently worse progression rates. This 
should encourage the initiation of management at this earlier stage to halt that 
progression. The KDIGO-2012-based definition16 identified more with stage 3 CKD as 
having progressed (at twice the rate of those with CKD stage 4). Because of the need for 
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both a percentage change and a stage change, the number of people identified follows a 
step distribution around the stage boundaries. The KDIGO definition preferentially 
identifies those with CKD stage 3 since a 25% reduction and stage change are more 
achievable in stage 3, thus favouring those with CKD stage 3 to have progressed. This 
should be borne in mind by others using this KDIGO suggested definition. Otherwise 
the predictors are similar to our definition.  
 
Others have explored different definitions of renal disease progression and support our 
finding that not all individuals end up on RRT or die. Hoefield et al.20 showed that at 
one year of follow-up over 50% of their stage 3a, 3b, 4 and 5 patients were still alive 
with the same or better stage of CKD. Baek et al.21 reported that at 10 years follow-up, 
64.3% of referred stage 3a and 27.2% of stage 3b remained at stage 3 or better 
(mortality only 2.3%). Several authors22 23  have reported that the decline in renal 
function over time is non-linear18, sometimes with prolonged episodes of slower decline 
in renal function18, but sometimes accelerated loss as eGFR declines23. Where reported, 
less proteinuria, higher eGFR, higher age, female sex, high serum albumin, lower BP 
and the use of ACE-inhibitors were associated with episodes of slower decline and the 
opposite for faster decline18 19 23 24. Some report that those with less proteinuria, eGFR 
≥40ml/min/1.73m2, ≤55 years of age, males, and with higher BP have a greater chance 
of having non-linear decline18. The use of linear regression for eGFR slope over time 
may not necessarily be a valid definition of progression. 
 
 
Death is a competing risk for both progression and RRT initiation (as previously 
demonstrated6, 25), with many people dying prior to reaching these end-points. However, 
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as illustrated by Grams et al.25, the use of competing risks analysis requires a good 
understanding of what you wish to demonstrate. In terms of demonstrating aetiological 
factors in an outcome of interest the cause-specific hazard ratio (or IRR used here) is the 
appropriate measure, subhazards (as calculated in competing risk analysis) might be 
more appropriate for estimating absolute risk25,26. Since we wished to explore whether 
the same aetiological factors had the same effect on progression and RRT outcomes, 
non-competing risks analysis was considered most appropriate.  
 
We have demonstrated a potentially useful definition of progression, where individuals 
who reached a predetermined reduction in eGFR during the six year follow-up 
displayed similar characteristics as those who initiated RRT.  The advantage of this 
definition of progression over RRT is that it could identify “high risk” people at a much 
earlier stage in their disease trajectory; a potential surrogate marker for the end 
outcome, RRT. This study was based on a prevalence cohort and the numbers 
advancing to RRT were too small to consider whether the time to achieve the new 
definition was associated with increased risk of RRT and over what timeframe would 
such a drop in function indicate a poorer prognosis. Also the minimal numbers with 
stage 3a CKD in this cohort limit the generalisability for those with less advanced CKD. 
Therefore, the use of this definition of progression as a potential surrogate marker for 
future RRT requirements needs to be explored in other datasets.  
 
This study used a well-described cohort with six years of follow-up. Access to all 
creatinine values within the region allowed an accurate reflection of the degree of 
progression that is measureable in a cohort with CKD identified opportunistically. 
There are issues that should be borne in mind when drawing conclusions from the 
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results of this study. Given the longitudinal capture of the data, there is a risk of 
confounding associated with increasing age, although this is likely to be small over a six 
year period. Ill-health, might lead to weight loss and therefore a reduction in the 
creatinine for an individual such that there appears to be no progression of disease using 
eGFR, whereas measured GFR might reveal otherwise; this effect also is likely to be 
small. The use of routine health care data, and both in-patient and out-patient bloods, 
although giving a realistic picture of the information available in routine clinical 
practice and on which treatment decisions are made, may not offer a complete picture. 
Data-linkage has limitations in that individuals may be misidentified, however the use 
of CHI plus other identifiers should minimise this. There will be relative over-sampling 
at times of ill health or acute illness and under-sampling at times when the individual is 
well and has more normal renal function. The way the cohort was created with a 
creatinine threshold of greater than 150μmol/L and 130μmol/L for males and females 
respectively means that for many the baseline eGFR slope up to the time of index was 
quite steeply negative.  However, for the majority, this became much less steep or even 
improved after the index. All these limitations, however, would reduce the incidence of 
this form of progression but we feel that the overall performance and associations found 
are valid despite these limitations.  
Conclusion 
In this article, we propose a novel definition of renal disease progression - a sustained 
reduction in eGFR by 15ml/min/1.73m2 (equivalent to a CKD stage transition) or to 
10ml/min/1.73m2, whichever occurs first. It is simpler and performs better at identifying 
those who will initiate RRT than the KDIGO-2012 definition. It allows direct 
comparison of this definition of progression to the traditional definition - RRT 
initiation. This facilitates comparison of the effect of the various predictors of 
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progression. We found that the association of greater RRT initiation rates amongst 
males and those with macroalbuminuria is mirrored in higher rates of progression. 
However CKD stage did not affect progression rates, despite being associated with RRT 
initiation rates. This suggests that interventions aimed at limiting progression (rather 
than preparation for RRT) might be better targeted if lead by these risk factors rather 
than CKD stage alone. 
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Table 1: Characteristics of the whole cohort (stage 3 and 4) and those who 
"progress", P-values for “progressors” versus non-progressors 
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Table 2: Rates of initiating RRT and "progression" by baseline characteristics; progression and RRT incidence rate ratios 
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Table 3: Outcome by 30th June 2009 (6 years follow-up) for cohort as a whole (stage 3 
and 4 CKD) non-progressors and progressors, by our definition and KDIGO 2012 
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Figure 1: Illustration of "progression" defined by a sustained 15ml/min/1.73m2 drop in 
eGFR. An illustrative plot for a hypothetical patient, presenting eGFR as measured 
over time within the study cohort. 
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Figure 2: First outcome of death, RRT or CKD stage at end of follow-up (30th June 
2009) 
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Figure 3: Kaplan-Meier sustained “progression”(a)our definition (b) KDIGO 2012 
definition, survival plots by index CKD stage (adjusted for males aged 75 years with 
normoalbuminuria) 
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Supplementary figure: Rates of progression and RRT initiation by baseline 
characteristics 
 
  
 
